Elderly patients with metastatic breast cancer (MBC) have more problems receiving chemotherapy than younger patients, especially with the presence of multiple comorbidities, adverse drug events and functional decline. Low-dose oral administration of cytotoxic agents such as vinorelbine, a semisynthetic vinca alkaloid that interferes with microtubule assembly, leading to arrest of cell division, is usually effective and well tolerated.
From February 2010 to February 2014, 32 patients with MBC, median age 76 years (range 69-83) were treated with oral vinorelbine 30 mg (total dose), one day on and one day off, until disease progression or unacceptable toxicity levels were reported. Toxicity, quality of life and clinical benefit were evaluated. Matched
No grade 3 and 4 adverse events were reported. A clinical benefit of 50% was found in our cohort. On and off metronomic vinorelbine oral administration resulted in good tolerability and safe profile in our selected elderly population, and improved patient adherence to therapy.
The present study demonstrated that metronomic vinorelbine might be a potential treatment in elderly patients by reducing adverse effects and increasing quality of life, setting the stage for future extensive clinical trials.
Tumori 2015; 101(1): 30 - 35
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsFrancesca De Iuliis, Gerardo Salerno, Ludovica Taglieri, Rosina Lanza, Susanna Scarpa
- • Accepted on 06/06/2014
- • Available online on 05/02/2015
- • Published in print on 20/03/2015
This article is available as full text PDF.
- Iuliis, Francesca De [PubMed] [Google Scholar] 1
- Salerno, Gerardo [PubMed] [Google Scholar] 1
- Taglieri, Ludovica [PubMed] [Google Scholar] 1
- Lanza, Rosina [PubMed] [Google Scholar] 2
- Scarpa, Susanna [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
Experimental Medicine Department, Sapienza University of Rome, Rome - Italy
Umberto I Hospital, Rome - Italy